1. Home
  2. TGTX vs KTB Comparison

TGTX vs KTB Comparison

Compare TGTX & KTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TGTX
  • KTB
  • Stock Information
  • Founded
  • TGTX 1993
  • KTB 2018
  • Country
  • TGTX United States
  • KTB United States
  • Employees
  • TGTX N/A
  • KTB N/A
  • Industry
  • TGTX Biotechnology: Pharmaceutical Preparations
  • KTB Apparel
  • Sector
  • TGTX Health Care
  • KTB Consumer Discretionary
  • Exchange
  • TGTX Nasdaq
  • KTB Nasdaq
  • Market Cap
  • TGTX 4.2B
  • KTB 3.6B
  • IPO Year
  • TGTX 1995
  • KTB N/A
  • Fundamental
  • Price
  • TGTX $29.45
  • KTB $77.39
  • Analyst Decision
  • TGTX Strong Buy
  • KTB Strong Buy
  • Analyst Count
  • TGTX 4
  • KTB 6
  • Target Price
  • TGTX $42.50
  • KTB $89.67
  • AVG Volume (30 Days)
  • TGTX 2.9M
  • KTB 935.6K
  • Earning Date
  • TGTX 08-04-2025
  • KTB 08-07-2025
  • Dividend Yield
  • TGTX N/A
  • KTB 2.68%
  • EPS Growth
  • TGTX N/A
  • KTB 5.71
  • EPS
  • TGTX 0.36
  • KTB 4.47
  • Revenue
  • TGTX $454,069,000.00
  • KTB $2,650,638,000.00
  • Revenue This Year
  • TGTX $84.00
  • KTB $20.34
  • Revenue Next Year
  • TGTX $39.26
  • KTB $11.09
  • P/E Ratio
  • TGTX $81.62
  • KTB $17.33
  • Revenue Growth
  • TGTX 30.96
  • KTB 3.44
  • 52 Week Low
  • TGTX $21.11
  • KTB $50.00
  • 52 Week High
  • TGTX $46.48
  • KTB $96.80
  • Technical
  • Relative Strength Index (RSI)
  • TGTX 42.03
  • KTB 73.54
  • Support Level
  • TGTX $27.23
  • KTB $70.75
  • Resistance Level
  • TGTX $28.85
  • KTB $73.53
  • Average True Range (ATR)
  • TGTX 1.11
  • KTB 2.33
  • MACD
  • TGTX 0.29
  • KTB 1.33
  • Stochastic Oscillator
  • TGTX 99.05
  • KTB 99.05

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

About KTB Kontoor Brands Inc.

Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

Share on Social Networks: